Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Malak Abedalthagafi

Neuropathology Washington, DC Medical Doctor

NPI 1760620355 CMS profile 2786595

3800 Reservoir Rd Nw, Washington, DC 20007

Open in the dashboard

General payments

$328

2 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Malak Abedalthagafi of Washington, DC is reported in the CMS Open Payments database as having received $328 across 2 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $328 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Malak Abedalthagafi
  • Neuropathology median
  • Middle half of Neuropathology
  • National median

In program year 2025, general payments to Malak Abedalthagafi were reported at $328. Among 23 Neuropathology profiles paid that year, the median was $97 and the middle half received between $32 and $342.

Show as a table
Year Malak Abedalthagafi Neuropathology median Middle half National median
2019 $0 $71 $26–$203 $163
2020 $0 — — $114
2021 $0 — — $132
2022 $0 — — $149
2023 $0 $51 $25–$132 $160
2024 $0 $74 $65–$748 $164
2025 $328 $97 $32–$342 $169

Breakdown

Who paid General payments · program year 2025
  1. Personal Genome Diagnostics Inc $181 1 payment
  2. Janssen Biotech, Inc. $147 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $328 2 payments
Products named General payments · program year 2025
  1. PGDX ELIO TISSUE COMPLETE $181 1 payment
  2. RYBREVANT $147 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$21,245

Medicare's payments for the services billed

Medicare patients

100

Average age 69

Services billed

695

58 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Diabetes 38%
Cancer 31%
Depression 31%
Chronic kidney disease 28%
Ischemic heart disease 26%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

2 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuropathology in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record